Genentech lists Phase Ib KRAS G12D trial; Roche-sponsored DLBCL study shows update
Two registry entries this week: a newly posted Genentech trial for KRAS G12D-mutated tumors and a Hoffmann-La Roche sponsored lymphoma study with a changed update date.
Two trial records surfaced in registry review this week.
- A Phase Ib study titled "A Phase Ib, Multicenter, Randomized Study Evaluating the Safety and Activity of GDC-7035 With Anti-Cancer Therapies as First-Line Treatment in Patients With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma"1 (NCT07859085) was listed as not yet recruiting, sponsored by Genentech, Inc. The record shows an estimated enrollment of 388 participants1, with an estimated start date of October 31, 2026, and an estimated primary completion date of March 30, 2029.
- The Phase Ib study of glofitamab combined with gemcitabine and oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma (NCT06624085), sponsored by Hoffmann-La Roche, showed a last update posted date of October 6, 2026, distinct from its October 2, 2024 first posting. The trial remains listed as active, not recruiting, with an estimated enrollment of 50 participants2 and a primary completion date estimated for March 22, 2027.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.